Thermo Fisher completes sale of anatomical pathology biz to PHC
01 July 2019 | News
The Anatomical Pathology business, with approximately 1200 employees in the U.S., Europe and Asia, generated approximately $350 million in annual revenue
Thermo Fisher Scientific, the world leader in serving science has recently completed the previously announced sale of its Anatomical Pathology business to PHC Holdings Corporation, a leading global healthcare company providing innovative solutions, for approximately $1.14 billion in cash.
The Anatomical Pathology business, with approximately 1200 employees in the U.S., Europe and Asia, generated approximately $350 million in annual revenue and was part of Thermo Fisher's Specialty Diagnostics Segment.
